
- /
- Supported exchanges
- / US
- / LEGN.NASDAQ
Legend Biotech Corp (LEGN NASDAQ) stock market data APIs
Legend Biotech Corp Financial Data Overview
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Legend Biotech Corp data using free add-ons & libraries
Get Legend Biotech Corp Fundamental Data
Legend Biotech Corp Fundamental data includes:
- Net Revenue: 728 M
- EBITDA: -228 340 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.254
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Legend Biotech Corp News

H.C. Wainwright Maintains a Buy on Legend Biotech (LEGN) With a $75 Price Target
Legend Biotech Corporation (NASDAQ:LEGN) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 2, analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating o...


Legend Biotech stock price target lowered to $54 at UBS on growth concerns
Investing.com - UBS has lowered its price target on Legend Biotech Corp . (NASDAQ:LEGN) to $54.00 from $60.00 while maintaining a Buy rating on the stock. According to InvestingPro data, the company ...

US High Growth Tech Stocks with Promising Potential
The United States market has shown robust performance recently, climbing 3.4% in the last 7 days and rising 14% over the past year, with earnings forecast to grow by 15% annually. In this thriving env...

Exploring Three High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has risen 2.7% and is up 13% over the last 12 months, with earnings forecasted to grow by 15% annually. In this environment of robust growth, identifying...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.